Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Revance Therapeutics, Inc.
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to severe crow's feet lines

• Female or male, 18 to 65 years of age and in good general health

• Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study

Exclusion Criteria:

• Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A

• Muscle weakness or paralysis, particularly in the area receiving study treatment

• Active skin disease or irritation at the treatment area

• Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart

• Treatment with Botulinum Toxin Type A for crow's feet lines in the last 6 months or 3 months anywhere in the body